A
Alcista
Alcista · 25%NVS
$136.39
Precio del escenario
$153.640
+3.518 (+2.29%)Al cierre
Loading chart…
- Máximo
- 153.680
- Apertura
- 152.150
- Precio medio ponderado por volumen
- 153.09
- Volumen
- 1.36M
- Capitalización
- 217.41B
- Mínimo
- 151.950
- Importe
- 207.73M
- EV/EBITDA, TTM
- 12.33
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Análisis de IA of Novartis AG (NVS)
MantenerNovartis AG is currently a hold. The stock is priced at $150.62, with a high RSI of 81.144 indicating it may be overbought. Despite a strong gross margin of 75.39% and a forward P/E of 14.71, recent pipeline setbacks, including the discontinuation of a key trial, raise concerns. The mixed analyst ratings suggest uncertainty, with only 8 out of 23 analysts recommending a buy. The main risk is the potential impact of clinical trial failures on future performance, which could affect investor confidence.
Recomendaciones de analistas (3)
-16.85% Potencial de caída
Mantener
1 Comprar
2 Mantener
0 Vender
Actual: 153.64
Mínimo
112.00
Promedio
127.75
Máximo
143.00
Morgan Stanley
Sobreponderar
$156
2026-10-06
Morgan Stanley
2026-10-06
Precio objetivo
$156
Sobreponderar
HSBC
Mantener
$136
2026-09-10
HSBC
2026-09-10
Precio objetivo
$136
Mantener
HSBC
Mantener
$110
2026-09-09
HSBC
2026-09-09
Precio objetivo
$110
Mantener
Citi
Comprar
$135
2026-09-09
Citi
2026-09-09
Precio objetivo
$135
Comprar
Deutsche Bank
Mantener
—
2026-09-09
Deutsche Bank
2026-09-09
Precio objetivo
—
Mantener
Métricas de valoración
El PER previsto actual de Novartis AG (NVS) es 14.71, frente a su media de 5 años de 13.24.
Escenarios de precio de Alphio AI para NVS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con NVS en cartera
Cronología de eventos
Noticias
9.510-16stocktwitsNovartis Faces Multiple Clinical Setbacks Amid Pipeline Challenges
7.510-06CNBCStarbucks Opens Stores in Xinjiang Amid Controversy
8.510-03stocktwitsNovartis Partners with Abogen in $7.8 Billion Deal
8.510-02CNBCNovartis Signs $7.8 Billion Deal with Chinese Biotech Abogen
2.010-02NewsfilterNovartis Enters $7.8 Billion Licensing Deal with Chinese Biotech
Preguntas frecuentes sobre NVS, respondidas por Alphio AI
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Novartis AG is currently a hold. The stock is priced at $150.62, with a high RSI of 81.144 indicating it may be overbought. Despite a strong gross margin of 75.39% and a forward P/E of 14.71, recent pipeline setbacks, including the discontinuation of a key trial, raise concerns. The mixed analyst ratings suggest uncertainty, with only 8 out of 23 analysts recommending a buy. The main risk is the potential impact of clinical trial failures on future performance, which could affect investor confidence.
3 analysts cover NVS: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 127.75.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.